Beacon Capital Management LLC (Tennessee)’s Oramed Pharmaceuticals ORMP Stock Holding History

Beacon Capital Management LLC (Tennessee)’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-219	Closed	-$493	–	746
2025 Q2	$493	Hold	219	–	–	﹤0.01%	1028
2025 Q1	$469	Hold	219	–	–	﹤0.01%	1083
2024 Q4	$530	Hold	219	–	–	﹤0.01%	1027
2024 Q3	$534	Hold	219	–	–	﹤0.01%	1143
2024 Q2	$563	Hold	219	–	–	﹤0.01%	990
2024 Q1	$639	Hold	219	–	–	﹤0.01%	996
2023 Q4	$572	Hold	219	–	–	﹤0.01%	914
2023 Q3	$784	Hold	219	–	–	﹤0.01%	941
2023 Q2	$784	Hold	219	–	–	﹤0.01%	941
2023 Q1	$477	Hold	219	–	–	﹤0.01%	884
2022 Q4	$2.63K	Buy	+219	New	+$1.7K	﹤0.01%	751

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Aquamarine Financial George Town $1.37B AUM

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Beacon Capital Management LLC (Tennessee)'s ORMP Position: Q3 2025 in Review

Beacon Capital Management LLC (Tennessee) sold out of Oramed Pharmaceuticals (ORMP) in Q3 2025, closing a stake of 219 shares — an estimated $493 sold.

Beacon Capital Management LLC (Tennessee) first reported a position in ORMP in Q4 2022 and held it in 11 quarters. The position peaked at $2.63K in Q4 2022. 47 funds tracked by Wall St. Rank hold ORMP as of Q3 2025.

Beacon Capital Management LLC (Tennessee) reported no remaining Oramed Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Beacon Capital Management LLC (Tennessee) sold 219 Oramed Pharmaceuticals shares in Q3 2025, an estimated $493.
Beacon Capital Management LLC (Tennessee) first reported a position in Oramed Pharmaceuticals in Q4 2022 and held it in 11 quarters.
Beacon Capital Management LLC (Tennessee)'s Oramed Pharmaceuticals position peaked at $2.63K in Q4 2022.
47 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2025.

Based on Beacon Capital Management LLC (Tennessee)'s 13F filing for Q3 2025, filed 7 Nov 2025.